Vertex Pharmaceuticals Inc

Company Profile

• Business description

  Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

• Contact

  50 Northern Avenue
  BostonMA02210
  USA

  T: +1 617 341-6100

  E: [email protected]

  https://www.vrtx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  6,400